22 completed. 22 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 22 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. Tislelizumab, Afatinib, Low dose radiotherapy - Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy | Phase 2 | Completed | West China Hospital | 98 | 2025-06-28 | 2026-06-30 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) Serplulimab and Chemotherapy - Non-small Cell Lung Cancer, Stage II-IIIA | Phase 2 | Completed | Fudan University | 30 | 2023-03-15 | 2025-10-01 |
| Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer xintilimab injection, Control - Neoadjuvant Chemoradiation Therapy, Rectal Cancer | Phase 2 / Phase 3 | Completed | Changhai Hospital | 201 | 2022-10-01 | 2026-01-02 |
| Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab - Immunotherapy, Gastric Cancer | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 189 | 2022-09-01 | 2026-04-01 |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Tislelizumab, Apatinib Mesylate, oxaliplatin - Immunotherapy, Gastrict Cancer | Phase 2 | Completed | Fujian Cancer Hospital | 40 | 2021-10-31 | 2025-03-18 |
| Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma Tislelizumab in combination with anlotinib - Pulmonary Pleomorphic Carcinoma, Immunotherapy | Phase 2 | Completed | Second Affiliated Hospital of Nanchang University | 29 | 2021-08-17 | 2026-05-28 |
| mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations - Colorectal Cancer, Immunotherapy | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 42 | 2021-05-01 | 2026-07-01 |
| Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel - Esophagus Cancer, Chemoradiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 35 | 2020-10-01 | 2025-05-30 |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) Anlotinib plus Sintilimab - Colorectal Cancer, Immunotherapy | Phase 2 | Completed | Shanghai Changzheng Hospital | 30 | 2020-06-01 | 2024-04-23 |
| Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma camrelizumab, Paclitaxel for injection (albumin-bound), Cisplatin - Esophageal Squamous Cell Carcinoma, Immunotherapy | Phase 2 | Completed | Guangzhou Institute of Respiratory Disease | 56 | 2020-01-17 | 2021-02-02 |
| Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy Dacarbazine (DTIC) - Immunotherapy | Phase 2 | Completed | University of Erlangen-Nürnberg Medical School | 38 | 2020-01-13 | 2026-02-10 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Completed | Lei Li | 34 | 2019-12-06 | 2022-03-15 |
| Omalizumab to Accelerate a Symptom-driven Multi-food OIT Omalizumab 16mg/kg, Omalizumab 8mg/kg, Placebo - Food IgE-mediated Allergy, Immunotherapy | Phase 2 | Completed | Philippe Bégin | 90 | 2019-11-11 | 2026-11-04 |
| Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG Part A) Healthy subjects, Part B) Advanced solid tumor - Immunotherapy | Phase 1 / Phase 2 | Completed | Ajou University School of Medicine | 24 | 2018-11-06 | 2021-07-06 |
| The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy Anlotinib in combination with Immune checkpoint inhibitors - NSCLC, Angiogenesis | Phase 1 / Phase 2 | Completed | The Affiliated Hospital of Qingdao University | 30 | 2018-06-01 | 2020-12-17 |
| MAPS & ITEC Cohorts: 6-8 Years Follow-up House dust-mite SLIT, Normal saline - Immunotherapy, Allergy and Immunology | Phase 2 | Completed | University of Southampton | 263 | 2017-09-15 | 2021-10-04 |
| ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma Nivolumab, Ipilimumab - Immunotherapy, Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 33 | 2017-02-28 | 2023-10-23 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Rectal Neoplasms (2) · Asthma (1) · Brain Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Hypersensitivity (1) · Prostatic Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Neoplasms by Site (15) · Neoplasms (14) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Neoplasms by Histologic Type (4) · Rectal Diseases (4) · Genital Diseases (3) · Head and Neck Neoplasms (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Urogenital Diseases (3)
anlotinib (3) · tislelizumab (3) · Albumin-Bound Paclitaxel (2) · Cisplatin (2) · Radiotherapy (2) · Afatinib (1) · Bevacizumab (1) · Chemoradiotherapy (1) · Dacarbazine (1) · Docetaxel (1) · Drug Therapy (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy (1) · Injections (1) · Ipilimumab (1)
Ajou University School of Medicine (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Changhai Hospital (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Dr. Ronnie Shapira (1) · Fudan University (1) · Fujian Cancer Hospital (1) · Guangzhou Institute of Respiratory Disease (1) · Lei Li (1) · MacroGenics (1) · Nantes University Hospital (1) · Philippe Bégin (1) · Radboud University Medical Center (1) · Second Affiliated Hospital of Nanchang University (1) · Shanghai Changzheng Hospital (1)
China (13) · France (2) · Netherlands (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Georgia (1) · Germany (1) · Israel (1) · Poland (1) · Puerto Rico (1) · South Korea (1) · Spain (1)
Dong-Ho Nahm (1) · Fred Witjes, MD PhD (1) · Graham Roberts, Prof (1) · Jolanda IM de Vries, PhD (1) · Jun Huang, MD (1) · Lei Li, M.D. (1) · Lotje Zuur, MD, PhD (1) · Pepi Pencheva, M.D. (1) · Ronnie Shapira-Frommer, Dr (1) · Winald R Gerritsen, MD PhD (1)
PMID 25539810, PMID 25846669, PMID 26073754, PMID 27389519, PMID 28159490, PMID 28734760, PMID 29398921, PMID 31727154, PMID 32328115, PMID 32358699, PMID 32514802, PMID 32698790, PMID 32824490, PMID 33189037, PMID 33194595, PMID 33282742, PMID 33607964, PMID 34937871, PMID 34957526, PMID 35665739, PMID 37709314, PMID 40954146, PMID 41894181, PMID 42114951